questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Indolizine
Indolizidines
Alcaloïdes indoliques
Alcaloïdes formés par condensation de sécologanine et de tryptamine
Alcaloïdes de Vinca
Vinblastine
Vinblastine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Vinblastine
Cancer
Diagnostic médical
Tests de laboratoire
Imagerie médicale
Vinblastine
Symptômes
2
Effets secondaires
Vinblastine
Nausées
Douleur
Vinblastine
Effets indésirables
Prévention
2
Prévention du cancer
Vinblastine
Traitement
Effets secondaires
Vinblastine
Médicaments antiémétiques
Traitements
2
Lymphome
Cancer du poumon
Vinblastine
Administration intraveineuse
Vinblastine
Traitement du cancer
Complications
2
Complications
Vinblastine
Infections
Moelle osseuse
Vinblastine
Dépression médullaire
Facteurs de risque
2
Facteurs de risque
Vinblastine
Maladies cardiaques
Vinblastine
Pédiatrie
Traitement du cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vinblastine : Questions médicales les plus fréquentes",
"headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-10",
"dateModified": "2025-05-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vinblastine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Alcaloïdes de Vinca",
"url": "https://questionsmedicales.fr/mesh/D014748",
"about": {
"@type": "MedicalCondition",
"name": "Alcaloïdes de Vinca",
"code": {
"@type": "MedicalCode",
"code": "D014748",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vinblastine",
"alternateName": "Vinblastine",
"code": {
"@type": "MedicalCode",
"code": "D014747",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Christine Chevreau",
"url": "https://questionsmedicales.fr/author/Christine%20Chevreau",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Oncopole, Toulouse, France."
}
},
{
"@type": "Person",
"name": "Stéphane Culine",
"url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr."
}
},
{
"@type": "Person",
"name": "Gwenaelle Gravis",
"url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France."
}
},
{
"@type": "Person",
"name": "Florence Joly",
"url": "https://questionsmedicales.fr/author/Florence%20Joly",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "[Diagnosis of leg edema].",
"datePublished": "2022-12-09",
"url": "https://questionsmedicales.fr/article/36484790",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00105-022-05082-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Radiomic Features of the Edema Region May Contribute to Grading Meningiomas With Peritumoral Edema.",
"datePublished": "2022-10-19",
"url": "https://questionsmedicales.fr/article/36259547",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jmri.28494"
}
},
{
"@type": "ScholarlyArticle",
"name": "Periorbital edema associated with alpelisib.",
"datePublished": "2022-06-22",
"url": "https://questionsmedicales.fr/article/35834907",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ctarc.2022.100596"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathogenesis of Reinke's Edema of the Vocal Fold.",
"datePublished": "2023-09-29",
"url": "https://questionsmedicales.fr/article/37772971",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/lary.31084"
}
},
{
"@type": "ScholarlyArticle",
"name": "Monitoring the skin structure during edema",
"datePublished": "2023-05-13",
"url": "https://questionsmedicales.fr/article/37193365",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1117/1.JBO.28.5.057002"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indolizine",
"item": "https://questionsmedicales.fr/mesh/D007212"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolizidines",
"item": "https://questionsmedicales.fr/mesh/D054836"
},
{
"@type": "ListItem",
"position": 7,
"name": "Alcaloïdes indoliques",
"item": "https://questionsmedicales.fr/mesh/D026121"
},
{
"@type": "ListItem",
"position": 8,
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"item": "https://questionsmedicales.fr/mesh/D046948"
},
{
"@type": "ListItem",
"position": 9,
"name": "Alcaloïdes de Vinca",
"item": "https://questionsmedicales.fr/mesh/D014748"
},
{
"@type": "ListItem",
"position": 10,
"name": "Vinblastine",
"item": "https://questionsmedicales.fr/mesh/D014747"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vinblastine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vinblastine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vinblastine",
"description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Edema#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vinblastine",
"description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Edema#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vinblastine",
"description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Edema#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vinblastine",
"description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Edema#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vinblastine",
"description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Edema#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vinblastine",
"description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Edema#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués."
}
},
{
"@type": "Question",
"name": "Quels tests précèdent l'administration de vinblastine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants de la vinblastine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux."
}
},
{
"@type": "Question",
"name": "La vinblastine provoque-t-elle des douleurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires de la vinblastine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine."
}
},
{
"@type": "Question",
"name": "Dans quels types de cancer la vinblastine est-elle utilisée ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule."
}
},
{
"@type": "Question",
"name": "Comment la vinblastine est-elle administrée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la vinblastine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des infections, des saignements et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "La vinblastine peut-elle affecter la moelle osseuse ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets indésirables avec la vinblastine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru."
}
},
{
"@type": "Question",
"name": "Les enfants peuvent-ils prendre de la vinblastine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/05/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Publications dans "Vinblastine" :
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020-07-30
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
British journal of haematology
2018-12-28
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
4 publications dans cette catégorie
Affiliations :
Department of Medicine, Oncopole, Toulouse, France.
Publications dans "Vinblastine" :
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
The Lancet. Oncology
2019-07-19
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, François Baclesse Cancer Center, Caen, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Jean Perrin Cancer Center, Clermont-Ferrand, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Pathology, René Huguenin Curie Institute, Saint Cloud, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
2 publications dans cette catégorie
Affiliations :
Programme in Developmental and Stem Cell Biology, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Plant Production Department, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Jena, Germany.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Massachusetts General Hospital Cancer Center, Boston, MA.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland; Department of Applied Pharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland.
Publications dans "Vinblastine" :
Edema of the lower extremities is always associated with a pathological condition that should be treated, especially in patients with chronic wounds. Because the underlying causes of edema can vary gr...
Meningiomas are frequently accompanied by peritumoral edema (PTE). The potential value of radiomic features of edema region in meningioma grading has not been investigated....
To investigate whether radiomic features of edema region contribute to grading meningiomas with PTE....
Retrospective....
A total of 444 patients including 196 grade II and 248 WHO grade I meningiomas: 356 patients for training, 88 for validation....
A 1.5-T/3.0-T, noncontrast T1-weighted (T1WI), T2-weighted (T2WI), contrast-enhanced T1-weighted (T1CE) spin echo sequences....
A total of 851 radiomic features were extracted from each sequence on each region (tumor and edema region). These features were integrated by region respectively. Three subsets of clinical-radiomic fe...
Stochastic Gradient Boosting, Random Forest, and Bagged AdaBoost predictive models were built based on each subset. Discriminative abilities of models were quantified using receiver operating characte...
Random Forest model based on combined subset (AUC [95% CI] = 0.880 [0.807-0.953]) had the best discriminative ability in grading meningiomas among the final models. The best model of edema subset and ...
Radiomic features of edema region may contribute to grading meningiomas with PTE. The Random Forest model based on combined subset surpasses the best model based on tumor or edema subset regarding gra...
4 TECHNICAL EFFICACY: Stage 3....
Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)...
The most frequent etiologic factor of Reinke's edema (RE) is considered to be smoking. However, the mechanism for the onset and development of the disease remains unclear. Hypoxia-inducible factor-1α ...
Surgical specimens of RE from patients who underwent endolaryngeal microsurgery were used. Normal vocal folds were used as a control group. Expression of HIF-1α and VEGF was analyzed by immunohistoche...
HIF-1α and VEGF were broadly expressed in the stromal, inflammatory, and endothelial cells in the lamina propria of the vocal fold of RE. The expression of HIF-1α and VEGF of RE were significantly hig...
Transcription factor HIF-1α and induced VEGF likely play roles in the pathogenesis of RE. And increased vascular permeability with fragile vessels in angiogenesis is likely to be an etiology of RE. Tr...
NA Laryngoscope, 134:1785-1791, 2024....
Edema occurs in the course of various skin diseases. It manifests itself in changes in water concentrations in skin layers: dermis and hypodermis and their thicknesses. In medicine and cosmetology, ob...
In this work, we have developed a method based on DRS with a spatial resolution (SR DRS), allowing us to simultaneously assess water content in the dermis, dermal thickness, and hypodermal thickness....
An experimental investigation of histamine included edema using SR DRS under the control of US was conducted. An approach for skin parameter determination was studied and confirmed using Monte-Carlo s...
It was shown that an interfiber distance of 1 mm yields a minimal relative error of water content determination in the dermis equal to 9.3%. The lowest error of hypodermal thickness estimation was ach...
This study demonstrates that measurement of the skin diffuse reflectance response at multiple distances makes it possible to determine the main parameters of the skin and will serve as the basis for t...
Insulin edema is an entity that should be considered in any patient who starts or intensifies an insulin regimen to improve metabolic control. Heart, liver, and kidney problems should always be ruled ...
Generalized subcutaneous edema is rare in dermatomyositis. We herein report an 82-year-old woman with dermatomyositis who presented with generalized subcutaneous edema. Three weeks before admission, s...
Fluid normally exchanges freely between the plasma and interstitial space and is returned primarily via the lymphatic system. This balance can be disturbed by diseases and medications. In inflammatory...
To assess the prevalence and clinical relevance of quadratus femoris muscle edema (QFME) in pediatric pelvic MRI....
The axial T2-W with fat saturation sequence of pelvic/hip MRI examinations of pediatric patients (≤ 18 years) and a control group of young adults aged 19-45 years was retrospectively and independently...
The study group included 119 children (164 MRI examinations; F:M 1:1.08, mean age 11.4 ± 3.6 years), and 120 young adults, > 18, < 45 years old, served as controls (F:M 1:0.9, mean age 33.7 ± 6.4 year...
QFME is significantly more prevalent in pediatric patients compared to adults under 45 years old, especially in subjects scanned for orthopedic indications. The clinical relevance of QFME in children ...
Edema, characterized by brain swelling, is a common response observed in various brain injuries. Timely detection of edema is crucial to mitigate the associated risks and improve patient care. This st...